Accelerant Holdings Agrees to Thoma Bravo Take-Private Merger
Accelerant Holdings (ARX) agreed to a take-private merger with Cherry Tree BidCo, affiliated with Thoma Bravo’s Discover Fund V. If completed, ARX shareholders will receive $20.25 per share plus a ticking amount, and ARX will be delisted. The deal needs two-thirds approval and regulatory clearances, with ACP holding about 82% voting rights to support it.
How this was made
The 30-second read
Why it matters
If completed, Accelerant will become wholly owned, shares will be cashed out at $20.25 plus any applicable ticking amount, and the company will be delisted and deregistered. The transaction is conditional on shareholder approval, antitrust/foreign investment clearances, and insurance regulatory approvals, with a go-shop through Sep 22, 2026.
Market read
This is a primary M&A disclosure with explicit cash consideration, delisting mechanics, and deal-approval conditions, creating a tradable spread and event-risk timeline.
What to watch
The go-shop period and fiduciary carve-outs mean a superior proposal is still possible; deal spreads can widen quickly on any competing bid rumors or regulatory friction.
Background
Accelerant Holdings is moving from public ownership toward a private equity-sponsored structure via a merger with Cherry Tree BidCo and Thoma Bravo-affiliated entities.
Ticker impact
Accelerant Holdings agreed to a Thoma Bravo-backed take-private merger, converting shares into $20.25 cash and delisting from NYSE.
Shares may trade with deal-spread dynamics until shareholder vote and regulatory approvals; downside risk if conditions fail or a superior bid emerges.
The article discloses a cash consideration ($20.25), delisting/deregistration, go-shop/no-shop structure, and committed financing with a large termination fee, which directly drives deal-spread behavior.
Market effects
Could signal continued private equity interest in regulated insurers and may affect deal expectations for other specialty insurance targets.
Limited direct regional spillover; primarily impacts US M&A and insurance deal sentiment.
Foreign investment and antitrust clearances highlight cross-border regulatory scrutiny that can influence similar transactions.
Counterpoint
The large termination fee and committed financing reduce execution risk, but insurance regulatory approvals can still be a gating factor that markets may underestimate.
Key entities
- companyAccelerant Holdings
Public insurer agreeing to be taken private in a cash merger and delisting from NYSE.
- acquirer vehicleCherry Tree BidCo
Merger counterparty that will merge into Accelerant under the agreement.
- private equity sponsorThoma Bravo
Backs the transaction through entities affiliated with its Discover Fund V.
- shareholderAltamont Capital Partners (ACP)
Holds about 82% of voting rights and entered a voting and support agreement to back the merger.
